CONGRESS | #ASCO21 | Longer follow-up in the MajesTEC-1 trial continues to support the RP2D for teclistamab of 1500 ug/kg sc weekly – presented by Amrita Krishnan @cityofhope #mmsm pic.twitter.com/eqIkjM0MNn
— Multiple Myeloma Hub (@MM_Hub) June 8, 2021